Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) Research & Development (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Research & Development readings, the most recent being $31.4 million for Q1 2026.

  • Quarterly Research & Development rose 27.59% to $31.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $116.6 million through Mar 2026, changed 0.12% year-over-year, with the annual reading at $109.8 million for FY2025, 3.73% down from the prior year.
  • Research & Development hit $31.4 million in Q1 2026 for Oric Pharmaceuticals, up from $25.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $32.0 million in Q4 2024 and bottomed at $13.8 million in Q2 2022.
  • Average Research & Development over 5 years is $23.7 million, with a median of $24.5 million recorded in 2023.
  • The largest annual shift saw Research & Development soared 54.04% in 2024 before it decreased 19.12% in 2025.
  • Oric Pharmaceuticals' Research & Development stood at $16.3 million in 2022, then surged by 50.24% to $24.5 million in 2023, then skyrocketed by 30.59% to $32.0 million in 2024, then decreased by 19.12% to $25.9 million in 2025, then grew by 21.58% to $31.4 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Research & Development are $31.4 million (Q1 2026), $25.9 million (Q4 2025), and $28.8 million (Q3 2025).